{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:23Z","timestamp":1787698463739,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.lungcan.2023.107216","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T01:59:12Z","timestamp":1682301552000},"page":"107216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1\/2, basket study"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-3064","authenticated-orcid":false,"given":"Matthew G.","family":"Krebs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jeffry Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"De Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen K.","family":"Angell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidalba","family":"Rocher-Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassondra","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Lin","family":"Ah-See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Herbolsheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107216_b0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-3-319-40389-2_14","article-title":"Small cell lung cancer","volume":"170","author":"Bernhardt","year":"2016","journal-title":"Cancer Treat. Res."},{"issue":"28","key":"10.1016\/j.lungcan.2023.107216_b0010","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10212","key":"10.1016\/j.lungcan.2023.107216_b0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.lungcan.2023.107216_b0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107216_b0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107216_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2023.107216_b0035","unstructured":"US Food and Drug Administration, Full Prescribing Information: Imfinzi (durvalumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761069s029lbl.pdf. (accessed 17 October 2022)."},{"key":"10.1016\/j.lungcan.2023.107216_b0040","unstructured":"European Medicines Compendium, Summary of Product Characteristics (Imfinzi 50 mg\/mL concentrate for solution for infusion). https:\/\/www.medicines.org.uk\/emc\/product\/9495\/smpc#gref. (accessed 17 October 2022)."},{"key":"10.1016\/j.lungcan.2023.107216_b0045","unstructured":"US Food and Drug Administration, Full Prescribing Information: Tecentriq (atezolizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s028lbl.pdf. (accessed 17 October 2022)."},{"key":"10.1016\/j.lungcan.2023.107216_b0050","unstructured":"European Medicines Compendium, Summary of Product Characteristics: Tecentriq (atezolizimab). https:\/\/www.medicines.org.uk\/emc\/product\/8442\/smpc#gref. (accessed 17 October 2022)."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107216_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107216_b0060","doi-asserted-by":"crossref","unstructured":"A.K.P. Ganti, B.W. Loo, M. Bassetti, C. Blakely, A. Chiang, T.A. D'Amico, C. D'Avella, A. Dowlati, R.J. Downey, M. Edelman, C. Florsheim, K.A. Gold, J.W. Goldman, J.C. Grecula, C. Hann, W. Iams, P. Iyengar, K. Kelly, M. Khalil, M. Koczywas, R.E. Merritt, N. Mohindra, J. Molina, C. Moran, S. Pokharel, S. Puri, A. Qin, C. Rusthoven, J. Sands, R. Santana-Davila, M. Shafique, S.N. Waqar, K.M. Gregory, M. Hughes, Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw. 19 (12) (2021) 1441\u20131464.","DOI":"10.6004\/jnccn.2021.0058"},{"key":"10.1016\/j.lungcan.2023.107216_b0065","doi-asserted-by":"crossref","unstructured":"T. Sen, B.L. Rodriguez, L. Chen, C.M.D. Corte, N. Morikawa, J. Fujimoto, S. Cristea, T. Nguyen, L. Diao, L. Li, Y. Fan, Y. Yang, J. Wang, B.S. Glisson, Wistuba, II, J. Sage, J.V. Heymach, D.L. Gibbons, L.A. Byers, Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer, Cancer Discov 9 (5) (2019) 646\u2013661.","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"10.1016\/j.lungcan.2023.107216_b0070","doi-asserted-by":"crossref","unstructured":"S. Jiao, W. Xia, H. Yamaguchi, Y. Wei, M.K. Chen, J.M. Hsu, J.L. Hsu, W.H. Yu, Y. Du, H.H. Lee, C.W. Li, C.K. Chou, S.O. Lim, S.S. Chang, J. Litton, B. Arun, G.N. Hortobagyi, M.C. Hung, PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression, Clin Cancer Res 23 (14) (2017) 3711\u20133720.","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107216_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7\u2013H3, B7\u2013H4 and TILs in human small cell lung Cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107216_b0080","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Schultheis","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107216_b0085","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107216_b0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","article-title":"PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer","volume":"12","author":"Yu","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107216_b0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107216_b0100","doi-asserted-by":"crossref","unstructured":"L.A. Byers, J. Wang, M.B. Nilsson, J. Fujimoto, P. Saintigny, J. Yordy, U. Giri, M. Peyton, Y.H. Fan, L. Diao, F. Masrorpour, L. Shen, W. Liu, B. Duchemann, P. Tumula, V. Bhardwaj, J. Welsh, S. Weber, B.S. Glisson, N. Kalhor, Wistuba, II, L. Girard, S.M. Lippman, G.B. Mills, K.R. Coombes, J.N. Weinstein, J.D. Minna, J.V. Heymach, Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1, Cancer Discov 2 (9) (2012) 798\u2013811.","DOI":"10.1158\/2159-8290.CD-12-0112"},{"key":"10.1016\/j.lungcan.2023.107216_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2022.07.007","article-title":"Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial","volume":"171","author":"Woll","year":"2022","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107216_b0110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107216_b0115","doi-asserted-by":"crossref","unstructured":"Y. Drew, B. Kaufman, S. Banerjee, A. Lortholary, S.H. Hong, Y.H. Park, S. Zimmermann, P. Roxburgh, M. Ferguson, R.H. Alvarez, S. Domchek, C. Gresty, H.K. Angell, V.R. Ros, K. Meyer, M. Lanasa, P. Herbolsheimer, M. de Jonge, 1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC), Ann. Oncol. 30 (2019) v485\u2013v486.","DOI":"10.1093\/annonc\/mdz253.016"},{"key":"10.1016\/j.lungcan.2023.107216_b0120","doi-asserted-by":"crossref","unstructured":"Y-J. Bang, B. Kaufman, R. Geva, S.M. Stemmer, S-H. Hong, J-S. Lee, S.M. Domchek, M.C. Lanasa, M. Tang, C. Gresty, H.K. Angell, L.L.M. Opincar, P.M. Herbolsheimer, T.R.J. Evans, An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer, J. Clin. Oncol. 37 (4_suppl) (2019) 140.","DOI":"10.1200\/JCO.2019.37.4_suppl.140"},{"key":"10.1016\/j.lungcan.2023.107216_b0125","doi-asserted-by":"crossref","unstructured":"M. Krebs, K. Ross, S. Kim, M. De Jonge, F. Barlesi, S. Postel-Vinay, S. Domchek, J. Lee, H. Angell, K. Bui, S. Chang, C. Gresty, P. Herbolsheimer, J. Delord, P1.15-004 An open-label, multitumor phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed SCLC, J. Thorac. Oncol. 12 (11) (2017) S2044\u2013S2045.","DOI":"10.1016\/j.jtho.2017.09.1040"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107216_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.lungcan.2023.107216_b0135","doi-asserted-by":"crossref","unstructured":"A.M. Goodman, S. Kato, L. Bazhenova, S.P. Patel, G.M. Frampton, V. Miller, P.J. Stephens, G.A. Daniels, R. Kurzrock, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol. Cancer Ther. 16 (11) (2017) 2598\u20132608.","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107216_b0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdl375","article-title":"Phase II trial of irinotecan\/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902","volume":"18","author":"Rocha-Lima","year":"2007","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2023.107216_b0145","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107216_b0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107216_b0155","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107216_b0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/cancers13040727","article-title":"PARP inhibitors in small-cell lung cancer: rational combinations to improve responses","volume":"13","author":"Knelson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.lungcan.2023.107216_b0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the Phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2023.107216_b0170","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107216_b0175","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.21037\/tlcr-20-362","article-title":"Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined","volume":"9","author":"Choua\u00efd","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107216_b0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107216_b0185","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, Phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223007547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:58Z","timestamp":1759237498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223007547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":37,"alternative-id":["S0169500223007547"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107216","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1\/2, basket study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107216"}}